Noticias y Actividades de Aptevo Therapeutics
Ejecutivos
Ver el organigrama con sus 14 ejecutivos principales
Biografías más buscadas en Aptevo Therapeutics
- Jeff Lamothe, Chief Executive Officer and Director
- Marvin White, Executive Chairman of the Board
- Barbara Lopez Kunz, Director
Recientes movimientos de ejecutivos en Aptevo Therapeutics
- Mary Janatpour, se ha incorporado a la empresa como Senior Vice President and Chief Scientific Officer (noticia publicada el 28 de mayo de 2026).
- Marvin White que ha sido Director, President and Chief Executive Officer, pasa a ser Executive Chairman of the Board (noticia publicada el 3 de febrero de 2026).
- John Niederhuber que ha sido Chairman of the Board, pasa a ser Lead Independent Director (noticia publicada el 3 de febrero de 2026).
Haga clic aquí para ver otros movimientos en Aptevo Therapeutics
Crear su alerta
para seguir los movimientos de los ejecutivos en Aptevo Therapeutics.
Biotecnología
Aptevo Therapeutics tiene 2.405 competidores entre los que se incluyen Eurofins (Luxemburgo), Lonza (Suiza) y BioNTech (Alemania).
Popular M&A news in Biotecnología
- IMU Biosciences acaba de anunciar una recaudación de fondos de 53 millones de dólares. (publicado el 3 de junio de 2026).
- NewLimit acaba de anunciar una recaudación de fondos de 435 millones de dólares. (publicado el 3 de junio de 2026).
- Rallybio and Avenzo Therapeutics have announced they will merge (publicado el 1 de junio de 2026)..
Otros contactos sugeridos en el sector Biotecnología
Noticias
Últimos comunicados de prensa de Aptevo Therapeutics
- Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia | Aptevo Therapeutics Inc
- Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights | Aptevo Therapeutics Inc
- APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting | Aptevo Therapeutics Inc
- Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia | Aptevo Therapeutics Inc
- Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update | Aptevo Therapeutics Inc
- Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update | Aptevo Therapeutics Inc
- Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022 | Aptevo Therapeutics Inc
- Aptevo Therapeutics Provides Update on Ongoing APVO436 Phase 1 Clinical Trial | Aptevo Therapeutics Inc
- Aptevo Therapeutics Reports Second Quarter 2020 Financial Results | Aptevo Therapeutics Inc
- Aptevo Therapeutics Secures $25 Million Non-Dilutive Financing from Midcap Financial Trust | Aptevo Therapeutics Inc
- View more press releases Close
Redes sociales sobre Aptevo Therapeutics
- Aptevo Therapeutics en Wikipedia, Google News y Yahoo Finance
- Aptevo Therapeutics en LinkedIn, Twitter y YouTube
